NEW YORK (GenomeWeb) – A German hospital is the first to integrate the Bio.logis Genetic Information Management Suite into a clinical genomics program, the company said today.
The Dr. Margarete Fischer-Bosch Institute for Clinical Pharmacology at Robert Bosch Hospital in Stuttgart is linking the new Bio.logis GIM platform into its information systems, including a genotyping platform and a web portal for patients to view their own pharmacogenomic data. Once the integration is complete in a few months, the Bio.logis suite will be able to send recommendations from a pharmacogenomic test directly to the ordering physician and to the patient, Frankfurt, Germany-based Bio.logis said.
"Straightforward therapy instructions can put treating physicians in a position to better categorize and reduce the risk of adverse side effects and therapy discontinuation," Institute for Clinical Pharmacology Director Matthias Schwab said in a statement. The web portal also will give patients easy access to their pharmacogenomic information for future treatments, whether at Bosch or another facility anywhere in the world, he added.
"The pharmacogenetic diagnostics concept now launched at [Robert Bosch Hospital] embodies the idea of personalized medicine with a comprehensive end-to-end solution for individual patients," said Bio.logis GIM Managing Director Enrico Just.
Bio.logis is a spinout of the Bio.logis Center for Human Genetics in Frankfurt.